The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.

CONCLUSIONS: This study provides novel insights into clinical beneficence of reducing excessive NET formation in SLE by therapeutic targeting ANA production with RTX + BLM. Altogether putting forward a new treatment concept that specifically ameliorates underlying SLE pathophysiology.
TRIAL REGISTRATION: ClinicalTrials.gov NCT02284984.
PMID: 29636274 [PubMed - as supplied by publisher]

Source: Journal of Autoimmunity - April 7, 2018 Category: Allergy & Immunology Authors: Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO Tags: J Autoimmun Source Type: research